SLS logoSLS
SELLAS Life Sciences Group Inc

46,224
Loading...
Loading...
News
all
press releases
Sellas Life Sciences Stock In Spotlight After Institutional Investor Exercises Existing Warrants
In consideration for the immediate exercise of the warrants in full, the institutional investor will receive new, unregistered warrants in a private placement to purchase up to 19.69 million shares of the company's common stock at an exercise price of $1.88.
Stocktwits·21d ago
News Placeholder
More News
News Placeholder
SELLAS Life Sciences Group (SLS) Upgraded to Buy: What Does It Mean for the Stock? (Revised)
SELLAS Life Sciences Group (SLS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·2mo ago
News Placeholder
Galena Biopharma (SLS) Upgraded to Buy: What Does It Mean for the Stock?
Zacks·3mo ago
News Placeholder
Galena Biopharma Upgraded to Buy: Here's What You Should Know
Investors might want to bet on Galena Biopharma, Inc. (NASDAQ: SLS), as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful...
Benzinga·1y ago
News Placeholder
SLS Stock Earnings: SELLAS Life Sciences Gr Misses EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips SLS stock results show that SELLAS Life Sciences Gr missed analyst estimates for earnings per share the fourth quarter of 2023. The post...
InvestorPlace·2y ago
News Placeholder
Sellas Life Sciences files $200M mixed securities shelf
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·2y ago
News Placeholder
Sellas Life Sciences files to sell 13.03M shares of common stock for holders
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·2y ago
News Placeholder
Sellas Life Sciences reports 2023 EPS ($1.34), consensus ($1.08)
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·2y ago
News Placeholder
SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update
Announced Phase 2a study of SLS009 in r/r AML Showing 50% Response Rate in the Selected Optimal Dose of 30 mg BIW Exceeding the Targeted 20% and 100% Response Rate in Patients with Identified...
Globe Newswire·2y ago
News Placeholder
GenFleet and BeiGene Enter into Trial Collaboration for a Potentially First-in-class Combination Therapy to Initiate Phase Ib/II Study of GFH009 (CDK9 inhibitor) and BRUKINSA (zanubrutinib) Treating Diffuse Large B Cell Lymphoma
GenFleet and BeiGene Enter into Trial Collaboration for a Potentially First-in-class Combination Therapy to Initiate Phase Ib/II Study of GFH009 (CDK9 inhibitor) and BRUKINSA (zanubrutinib) Treating...
PR Newswire·2y ago

Latest SLS News

View

Advertisement|Remove ads.

Advertisement|Remove ads.